signature=2115bd79e3ad7a14f6ec4efd5feb6a3c,infi-20200730

0001113148-20-000027.txt : 20200730

0001113148-20-000027.hdr.sgml : 20200730

20200730190313

ACCESSION NUMBER:0001113148-20-000027

CONFORMED SUBMISSION TYPE:8-K

PUBLIC DOCUMENT COUNT:16

CONFORMED PERIOD OF REPORT:20200730

ITEM INFORMATION:Results of Operations and Financial Condition

ITEM INFORMATION:Financial Statements and Exhibits

FILED AS OF DATE:20200730

DATE AS OF CHANGE:20200730

FILER:

COMPANY DATA:

COMPANY CONFORMED NAME:INFINITY PHARMACEUTICALS, INC.

CENTRAL INDEX KEY:0001113148

STANDARD INDUSTRIAL CLASSIFICATION:PHARMACEUTICAL PREPARATIONS [2834]

IRS NUMBER:330655706

STATE OF INCORPORATION:DE

FISCAL YEAR END:1231

FILING VALUES:

FORM TYPE:8-K

SEC ACT:1934 Act

SEC FILE NUMBER:000-31141

FILM NUMBER:201061759

BUSINESS ADDRESS:

STREET 1:1100 MASSACHUSETTS AVENUE

STREET 2:FLOOR 4

CITY:CAMBRIDGE

STATE:MA

ZIP:02138

BUSINESS PHONE:6174531000

MAIL ADDRESS:

STREET 1:1100 MASSACHUSETTS AVENUE

STREET 2:FLOOR 4

CITY:CAMBRIDGE

STATE:MA

ZIP:02138

FORMER COMPANY:

FORMER CONFORMED NAME:INFINITY PHARMACEUTICALS, INC./NEW/

DATE OF NAME CHANGE:20060913

FORMER COMPANY:

FORMER CONFORMED NAME:DISCOVERY PARTNERS INTERNATIONAL INC

DATE OF NAME CHANGE:20000428

8-K

infi-20200730.htm

8-K

infi-20200730

FALSE000111314800011131482020-07-302020-07-30

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 30, 2020

Infinity Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware000-3114133-0655706

(State or other jurisdiction

of incorporation)(Commission File Number)(IRS Employer

Identification No.)

1100 Massachusetts Avenue, Floor 4, Cambridge, MA02138

(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code: (617) 453-1000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of ClassTrading SymbolName of Exchange on Which Registered

Common Stock, $0.001 par valueINFINasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.¨

Item 2.02. Results of Operations and Financial Condition.

On July 30, 2020, Infinity Pharmaceuticals, Inc. (the "Company") issued a press release announcing its results for the quarter ended June 30, 2020 and will conduct a previously announced, publicly available conference call to discuss those results. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained on the websites referenced in the press release is not incorporated herein.

This information and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) The following exhibit is included in this report:

Exhibit No.Description

104Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INFINITY PHARMACEUTICALS, INC.

Date: July 30, 2020By:/s/ Seth A. Tasker

Seth A. Tasker

Chief Business Officer

EX-99.1

pressrelease2020q210q.htm

EX-99.1

Document

Exhibit 99.1

Infinity Pharmaceuticals Provides Company Update and Second Quarter 2020 Financial Results

– MARIO-275 Dose Reduction Effective in Reducing Liver Enzyme Elevations. Interim Efficacy Analysis

Expected by Year End. –

– Encouraging Early Clinical Activity in MARIO-3 Front-Line Triple Negative Breast Cancer Cohort to

be Presented by Year End –

– Cash Runway into 2H2021 –

CAMBRIDGE, Mass., July 30, 2020 /Business Wire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its second quarter 2020 financial results and provided an update on the company, including its second quarter progress with eganelisib (also known as IPI-549), the company’s first-in-class, oral immuno-oncology product candidate targeting immune-suppressive tumor-associated myeloid cells through selective phosphoinositide-3-kinase-gamma (PI3K-gamma) inhibition.

“We have made important clinical progress this quarter including the generation of early, but encouraging signals of clinical activity in the triple negative breast cancer cohort of MARIO-3,” said Adelene Perkins, Chief Executive Officer and Chair of Infinity Pharmaceuticals. “While these data are preliminary, we are excited by the potential to bring eganelisib to the front-line setting for the deadliest form of breast cancer and plan to present these data later this year.”

Ms. Perkins continued, “We are also pleased that the dose reduction implemented for MARIO-275 from 40mg QD to 30mg QD has enabled the continued treatment of patients previously enrolled in the study. We will conduct an interim efficacy analysis on these patients by the end of the year which will inform next steps.”

Key Q2 2020 Updates:

Clinical and Regulatory:

•MARIO-275: MARIO-275 is the company’s ongoing controlled, randomized Phase 2 study evaluating eganelisib in combination with Opdivo®in platinum-refractory, I/O naïve patients with advanced urothelial cancer (aUC), in collaboration with Bristol Myers Squibb, or BMS.

◦Infinity implemented a dose reduction from 40mg QD to 30mg QD which has reduced the reversible liver enzyme elevations which were reported at the first scheduled MARIO-275 Independent Data Monitoring Committee (IDMC) meeting. Infinity will continue treatment of the currently enrolled patients and conduct an interim efficacy analysis by the end of the year which will inform next steps.

•MARIO-3: MARIO-3 is the company’songoing Phase 2 study in collaboration with Roche/Genentech to evaluate eganelisib in novel triple combination in the front-line setting with Tecentriq®and Abraxane®in triple negative breast cancer (TNBC) and with Tecentriq and Avastin®in renal cell cancer (RCC).

◦Early, encouraging clinical activity has been observed in the TNBC cohort of MARIO-3. Infinity plans to present these initial clinical data later this year.

◦The majority of identified sites are up and running. Infinity has observed an increase in site initiation and patient screening, and Infinity is working closely with the CRO on enrollment initiatives.

◦Enrollment completion is expected in the RCC cohort by the end of 2020 and the TNBC cohort by the end of Q1 2021.

•MARIO-1: Infinityplans to share clinical and translational data from MARIO-1 later this year.

•Arcus Collaboration: A Phase 1b collaboration study with Arcus Biosciences, which is being conducted by Arcus, is evaluating a checkpoint-inhibitor free, novel triple-combination regimen of eganelisib + AB928 (dual adenosine receptor antagonist) + Doxil®in up to approximately 40 advanced TNBC patients.

•COVID-19 Impact: As the situation with COVID-19 continues to evolve, the company is diligently evaluating impacts on enrollment, site initiations, patient treatment and protocol compliance. Infinity continues to work closely with trial sites to support the continued treatment of patients in compliance with study protocols and is proactively working to mitigate disruptions to enrollment and trial timelines.

Corporate:

•Dr. Brian Schwartz joined Infinity in a consulting Chief Physicianrole in April. He is actively providing guidance and insight across Infinity’s clinical programs, leveraging his deep experience in clinical development, particularly in oncology.Dr. Schwartz brings an impressive track record of experience and success, most recently serving as Chief Medical Officer at ArQule up until its acquisition by Merck. Dr. Schwartz is providing guidance and insight across Infinity’s clinical programs, leveraging his deep experience in clinical development, particularly in oncology.

Second Quarter 2020 Financial Results:

•At June 30, 2020, Infinity had total cash, cash equivalents and available-for-sale securities of $42.7 million, compared to $50.3 million at March 31, 2020.

•Research and development expense for the second quarter of 2020 was $6.1 million, compared to $6.1 million for the same period in 2019.

•General and administrative expense was $2.9 million for the second quarter of 2020, compared to $3.8 million for the same period in 2019. The decrease is primarily related to a decrease in consulting and stock compensation.

•Net loss for the second quarter of 2020 was $9.5 million, or a basic and diluted loss per common share of $0.16, compared to a net loss of $10.5 million, or a basic and diluted loss per common share of $0.18 for the same period in 2019.

2020 Financial Outlook:

Net Loss: Infinity expects net loss for 2020 to range from $35 million to $45 million.

Cash and Investments: Infinity expects to end 2020 with a year-end cash, cash equivalents and available-for-sale securities balance ranging from $20 million to $30 million.

Cash Runway: Based on its current operational plans, Infinity expects that its existing cash, cash equivalents and available-for-sale securities, will be adequate to satisfy the company's capital needs into 2H2021. Infinity's financial guidance does not include potential additional funding or business development activities, a potential $5 million milestone payment from BVF based on PellePharm’s ongoing Phase 3 clinical trial of patidegib topical gel in Gorlin Syndrome, or any milestones from, or the sale of the company’s equity interest in, PellePharm.

Conference Call Information

Infinity will host a conference call today, July 30, 2020, at 4:30 p.m. ET to discuss these financial results and company updates. A live webcast of the conference call can be accessed in the "Investors/Media" section of Infinity's website at www.infi.com. To participate in the conference call, please dial (877) 316-5293 (domestic) and (631) 291-4526 (international) five minutes prior to start time. The conference ID number is 7893533. An archived version of the webcast will be available on Infinity's website for 30 days.

About Infinity and Eganelisib

Infinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is advancing eganelisib, a first-in-class, oral immuno-oncology development candidate that selectively inhibits PI3K-gamma, in multiple clinical studies. MARIO-275 is a global, randomized, controlled combination study of eganelisib combined with Opdivo®in I/O naïve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq®and Abraxane®in front-line TNBC and in combination with Tecentriq and Avastin®in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus AB928 (dual adenosine receptor antagonist) plus Doxil®in advanced TNBC patients. In 2019, Infinity completed enrollment in MARIO-1, a Phase 1/1b study evaluating eganelisib as a monotherapy and in combination with Opdivo (nivolumab) in patients with advanced solid tumors including patients refractory to checkpoint inhibitor therapy. With these studies Infinity is evaluating eganelisib in the anti-PD-1 refractory, I/O-naïve, and front-line settings. For more information on Infinity, please refer to Infinity's website at www.infi.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding: the therapeutic potential of eganelisib; plans to present data; planned analyses in MARIO-275; clinical trial enrollment projections; the impact of the COVID-19 pandemic on the company’s clinical studies, business operations and financial guidance; the timing of further clinical trial updates from the company; the company’s guidance with respect to net loss, cash and cash equivalents and cash runway; and the company's ability to execute on its strategic plans. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. For example, there can be no guarantee that eganelisib will successfully complete necessary preclinical and clinical development phases. Further, there can be no guarantee that any positive developments in Infinity's product portfolio will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: the cost, timing and results of clinical trials and other development activities that may be delayed or disrupted by the COVID-19 pandemic or otherwise; the outcome of the company’s risk/benefit review of its MARIO-275 clinical trial; the content and timing of decisions made by the U.S. FDA and other regulatory authorities; Infinity's ability to obtain and maintain requisite regulatory approvals; unplanned cash requirements and expenditures; development of agents by Infinity's competitors for diseases in which Infinity is currently developing or intends to develop eganelisib; and Infinity's ability to obtain, maintain and enforce patent and other intellectual property protection for eganelisib. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" included in Infinity's annual report and quarterly reports filed with the Securities and Exchange Commission (SEC), and in other filings that Infinity makes with the SEC, available through the company’s website at www.infi.com. Any forward-looking statements contained in this press release speak only as of the date hereof, and Infinity does not undertake and expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Opdivo®is a registered trademark of Bristol-Myers Squibb.

Tecentriq®and Avastin®are registered trademarks of Roche.

Abraxane®is a registered trademark of Celgene.

Doxil®is a registered trademark of Janssen Products.

Copiktra®is a registered trademark of Verastem, Inc.

INFINITY PHARMACEUTICALS, INC.

Condensed Consolidated Balance Sheets

(in thousands)

(unaudited)

June 30, 2020December 31, 2019

Cash, cash equivalents and available-for-sale securities$42,730$42,444

Other current assets2,0642,137

Property and equipment, net1,9512,186

Other long-term assets1,9112,247

Total assets$48,656$49,014

Accounts payable and accrued expenses$8,877$9,698

Liability related to sale of future royalties, net128,72129,626

Liability related to sale of future royalties to a related party, net220,366—

Operating lease liability, less current portion1,6881,926

Long-term liabilities38838

Total stockholders’ equity (deficit)(11,384)7,726

Total liabilities and stockholders’ equity (deficit)$48,656$49,014

1In the first quarter of 2019, Infinity recognized $30.0 million in gross cash proceeds received from the HealthCare Royalty Partners III, L.P. (HCR) agreement as a liability on the balance sheet in accordance with accounting guidance for royalty monetization. While recognized as a liability, the Company is not obligated to repay the $30.0 million from HCR.

2In the first quarter of 2020, Infinity recognized $20.0 million in gross cash proceeds received from the Biotech Value Fund Partners, L.P. (BVF) funding agreement as a liability on the balance sheet in accordance with accounting guidance for royalty monetization. While recognized as a liability, the Company is not obligated to repay the $20.0 million from BVF.

INFINITY PHARMACEUTICALS, INC.

Condensed Consolidated Statements of Operations

(in thousands, except share and per share amounts)

(unaudited)

Three Months Ended June 30,Six Months Ended June 30,

2020201920202019

Collaboration revenue$—$—$—$2,000

Royalty revenue360257788399

Total revenues3602577882,399

Operating expenses:

Research and development6,1256,07613,47011,842

General and administrative2,9373,7716,2617,169

Royalty expense12171554756,916

Total operating expenses9,27910,00220,20625,927

Loss from operations(8,919)(9,745)(19,418)(23,528)

Other income (expense):

Investment and other income50318235607

Interest expense(39)(1,087)(77)(1,391)

Related party interest expense2(565)—(1,099)—

Total other expense(554)(769)(941)(784)

Loss before income taxes(9,473)(10,514)(20,359)(24,312)

Income taxes benefit———54

Net loss$(9,473)$(10,514)$(20,359)$(24,258)

Basic and diluted loss per common share:$(0.16)$(0.18)$(0.35)$(0.43)

Basic and diluted weighted average number of common shares outstanding:57,442,32256,942,03357,392,96556,933,521

1In the first quarter of 2019, Infinity recognized $6.7 million of royalty expense, which reflects Takeda’s share of the $30.0 million gross proceeds received from HCR for the monetization of Copiktra royalties.

2In the first quarter of 2020, Infinity recognized $20.0 million in gross cash proceeds received from the BVF funding agreement as a liability that will be amortized using the effective interest method over the life of the arrangement, in accordance with accounting guidance for royalty monetization.

Contact

Ashley Robinson

LifeSci Advisors, LLC

617-775-5956

[email protected]

EX-101.SCH

infi-20200730.xsd

XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT

0001001 - Document - Cover

link:presentationLink

link:calculationLink

link:definitionLink

EX-101.CAL

infi-20200730_cal.xml

XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT

EX-101.DEF

infi-20200730_def.xml

XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT

EX-101.LAB

infi-20200730_lab.xml

XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT

Written Communications

Pre-commencement Tender Offer

Entity Incorporation, State or Country Code

Entity Address, City or Town

Soliciting Material

Entity Address, Address Line One

Security Exchange Name

Entity Address, Address Line Two

City Area Code

Cover [Abstract]

Entity Central Index Key

Entity Tax Identification Number

Entity File Number

Document Type

Entity Emerging Growth Company

Title of 12(b) Security

Amendment Flag

Local Phone Number

Entity Address, State or Province

Entity Address, Postal Zip Code

Trading Symbol

Pre-commencement Issuer Tender Offer

Document Period End Date

Entity Registrant Name

EX-101.PRE

infi-20200730_pre.xml

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

GRAPHIC

headera0311.jpg

GRAPHIC

begin 644 headera0311.jpg

M_]C_X 02D9)1@ ! $ 8 !@ #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC

M+B!6,2XP,0#_VP"$ (" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("

M @(" @,# @(# @(" P0# P,#! 0$ @,$! 0$! ,$! ,! @(" @(" @(" @,"

M @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#

M P,# P,# __$ :( $% 0$! 0$! ! @,$!08'" D*"P$ P$!

M 0$! 0$! 0 $" P0%!@H.$A8:'

MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q+CY.7FY^CIZO'R\_3U]O?X^?H1 (! @0$ P0'!00$ $"=P ! @,1

M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)BH*#A(6&

MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76

MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_ !$( %8"MP,!$0 "$0$#$0'_V@ ,

M P$ A$#$0 _ /W\Z?A_2@#RCXS?&/P=\#/ FI>/?&MQ=)IMD\5I96.GVYNM

M3UC5;I9?L6E:?;Y53/+Y4CEY)(XXXX99)'5(V-=6$PE7%UHTJ:TNN:6GNQYD

MG*SKC&32UU:3TO9VVM?H?E/K'_!6K5X[Z;^Q?@E:I

MIJX,!UGQ;,;]E&*?^B,: ,>OBS41C'UT>NW_5&/_0:__!2_^6&7

M]MR7_+BUO[__ -H36W_!6CQC>7-O9VGP2T2XNKJ:*WMK>#Q3J7_+SHNUWV3"&=SG*-

M.GA^:&M

M2U#Q'XJTH7$<9]1>#/&WA_P =Z2-6

MT"[,\*R>3<6\R>5=VG0ZKKTL

M=;D"H'M\@R!2;4=]+!V_ ,@4E)/9[ ]/(,BG="NA:8PHV^0"9 ]L?AC%*Z5O

M/1!:WR$W#W&/8C]<=/>G^@KK3\!V/PQBC;Y"30FX#U'.!P1S^73WZ4KK[BK-?(76FWR

MI=$]$%F&10OR%:WR%H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H

M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "

M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H :2 #S@ 'G&<8'I

MCM4J4;I7U;22\^@;*_1'XY?M=?$31?B[XS7P[;ZHDOAGP9)%A%N/+4DTY;;::;O9K\VMSSZSC

M4E;>+T?IK?L^I\;3_#+0;H_(]J^4\O<2PP23Q\T@Z;A^=>LJTHZ_RZ_=\C%X

M:A9I+7I\7^9@W7P8L)=QC6V;;EF[_ /DCZJ^!7P%T+X3V5C\4-6TNWU/Q_KR&'X7:=/"+@>'K-9"E

MUX]>'YE_M/SHY+?2]X A=)[P!BEL]>3CLSJ3_N

MVFMV=$,MI4YPG%:P::WW3NOM>1[E;^!-2O6-UJE^L4\S-)*OSW=P9)&\QGFD

M>11YK,Q+$LY+$LV2QKR9XJCR2Y9^]9V]V6]M-U8]#DDNFWH>J?">[U+X9^+(

M+R6[6[\.:J%T_6T *RVL!O[0_P 1

M?V=_!_@/6?AW-H\%]X@\27^F:@VL:6FJ0FUMM.%S$(HVFC,4GFY^8;N.#7L9

M!@H8VM7AB(W48.45=K:4$G[LH]]F>7F6*>&C247RMM=/*7=/L:/[!_Q^^(/[

M0?PY\7^)_B)/I$^IZ)XUDT*Q.C:8NF6XL$T+1]0"RPAWWR_:+Z8[]W0*,#;\

MV.WE88P.I4E#G XX(_A##KCL1235[=MQ

MVM:^B_0^,?VW/VCM>_9S^%ECK/A.QM+GQ9XKUO\ X1O1;R^1);'12+"[OKK5

MIK1GQ>S11VR1PP,0ADN \FY(FCD]C)SJWY8I-1U2DG*,;-II]=TUK

M;IH_+S'%SPT.:FK+6*E=/WK2:TL^U]4?EY\/_CU_P4C^+>FW_B#X;ZUX@\3Z

M-9ZD^G7-[IGA'X;PV=OJ!BCNC8Q/?:'#O>.WN+=B )"JS1%R?,4M]%B\OR#!

M2]GB+4IV=E_M#VNOLRDM&OE\T>33QF:UHMT%S-;?PEKT^**2W6Y]._M2_%/]

MM'P5#\%+?X:1>/1J>I?"70[_ .(Z^'OA[IWBE!XZ),>K?;Y(O"^H0:?>B57S

M;VS0Q ;2D>PJ:XOFL%0

MA"/[QT8.:_^&>L^/%OO\ A,]4\&Z!?>*#

MJ6GKI5^-:N+"&341>:7':6R:?XI/E?O>]M;1Z]SU*,JZH4?:Z57R8L;%-J[#EMP&!@UM14)5*

M:E;V?-%2W6EU?6]UIV,I\\(2Y86E%-K5/5+31Z;]S\8_V#RJE@O:TH\M:,+MWK:-0;^U)QTDEI;\#R,+B\PEBW3JZ4%)K:E\/

M.E]F/-\-_/YGVG^VA^TUXH_9E\*>#?$'ACP[H/B"?Q'KU[I-U!KKZ@D4$-MI

MXNTDMS87,3>:7X.\D8Z#->9E>7PS*I.CS.,5%.ZMLVHWL[7T>R:9W8W%RPRB

MUI%]?OMI9O9'4_L?_'SQ!^T7\++OQ[XCT32-!O[7QCJWAQ;/1GNVM6MM.T_1

M;R.X8WD\K^71RRNL/"7,I14EI;3FE'O+^2^_4TP>*C

MB*3ES7LW'9K6T7;9=_0^KJ\TZ@Z?A_2@-OD)N'KT^O&*=F@M:WGM^AS7B/4=

M7TZ*PETI-.D6?4K#3[E;_P"U!E&H7UK912P"W^\8S.SLK8R$XYHL^VP^5]MC

MS[P-\5I?&'B,>')-&?3KFUT?4K_4F@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *

M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H

M * "@ H * "@ H * "@ H * "@ H ^%OV\_VB%^!OPCDTC1[OR/'7Q&^U^']

M!\IHS/IFE)%&OB+7-K E##:7,=I"ZCSP5"JZEU.SA%+7WVFDKWLDF

MFVWT3W=D_1P>(6*FO8RYE&7O:6M9J^Z6UUL?K%\1O![>'/$\M^L9>SO[6TAT

MR4HHBT[3K&%+>#1+1%XM[:T6!=JJ!N#JS$LW'QU2I.5K/1;Z)=7=[+>]SVE'

ME:UM;]#A1R !D[?E7))Q@Y R?<77w m:2l>Q)^;G_ 5I

M_P"2"G/;QIJN/PT8>E?4\)V^N54_\ GU_[?3/GL]T5)[)22^?OGF'[$?C#

M7O /[%7[3'C+PM>KI_B'POK>MZQHUZ]K:WJ6NH6O@[P])!*]I>P2P7"[D *2

MQNI':NG/Z5.IG.!HVYHU%3BUJKIUIJU[IJ][731&73E3R_%5(RLX.HUIU5.+

M6_IV/)OAG_P4R^.NAW?B"7QR]K\2+B[T%M/\'Z%'H>@Z%9V_BFZU+3OLFIZE

M/H&DV][>6D-A%J4?V*&0-/)=0H&BQYT797X;P=54517U:,>5U9^SXL+G.)A.K[6/M'[RIQ]U*]X\K?+%.R5]-W^*V?%'Q3_P""

MG6H6,_CRXT?XC>'M @=]0^P:-X%TJPMK"T5%E(?0I=+FU2;3HXDR7O4N!MW&

M1V+,24L+PQ%K#J5&I-KEO.K)MO;XKJ";[*WDC:=?.FG5Y:D(+6T8))+_ V<

MK>IZ+^R1_P %"?B-K?Q \/?#3XU3V'B&Q\7ZA::#HOBN#3;+2-5TG7=0D2VT

MJ/5(=-@MK2^T^YNGC@D<0Q3Q/*)6D=%93Q9IP]1I477P:?[N;E*FKKEIJ,I.

MSG-W?5?!6E^'(9=22&YB7R;W3]'M#=[M-+':[2)M.[[V"/7R

M2AE:4OJTU+$1I)U(KVFZY;ZM\J][2ZT[:(\_,*V+4OWT.6BZEXN\/A]ZS]U7

M^'H]>^I9_9L^('[:7A;P%?6/[/>A>)M2\$R>)+V[O+C2_ .E^)K=/$#:?I4%

MY";[4-&NI8Y5L8-,8VXD "R(X4>9EHS2GDWM.7'6I5G!N*:\F?8W[7?[5_[1OP6C^!EAHGB"+PUKOB

M;X1:)K_CK3]1\*^'KF[_ .$PD8PZJ9H-2TJ7^SWCN(Y8VMH/)C5@PV 8QX^5

MY5@L8L5.%/VU.G6J*'O3C>G%0:6LTU>^[NU?R.W,,7CL,L.O:%?$]I9>*_B-H45WXNOY?#OAZ\CU

M.[?P]IE\SQV-YI\MMIZ_:[B5PMK'"HW[=NQ0HC+LNPF(S',,-5HWC04_9PYY

MKV;C.,4^923ERWMJVI;FV+QN)IY?A*L*GOS]GS>[%7O3;:V:6W1(^?\ PG_P

M4&_:C\;^$].^'G@'P[+XS^+U_J&JW>H>)[+PG8:ABA;6.PM-%\-Z+8QV2

M-;LMQ)/J.H6\B 3HGE_+Y@[O[ R^C.>(QE7V.&A[J@Y\B;NW>4W*3LU9*,6G

MH_GRT\TQKIQH4:?-7EJVHJ32LE91BDM&G=M6V.)\=_'/_@HS\'6@\2?$+5?'

MOAW3KJ2&-+S5?"WA:\\.&977RK622#1;C3K2YD,6/)=HI) 6.TAB3UT:,JF*S?"M3K>T4;K1J/*_[MTFHM[?H?HU

M^Q5^V-JO[16A>*?#_C"QT[3?B+X,T^'5))]*@DM].\0:+-']G75%LY995L[R

MWU 1QW$23!&^V0M"B*66/Y[-,@HX/$X=PE?#5*M.+W6\I>ZKRE)7C&]WL_N7

MHX3-:M:G5@J/+5A3E+XHZ625]8Q3M)[?@?&/[,_[;7[1_P 2/CYX%\!^*/&M

MCJOA_7=1UZVO--A\(^&+22X6S\.:U>64:W=GI5M<1G[7:6S_ "2J=R88E&*G

MU\5DF5T_/5Z0;V]H^W8X2>&Y=6\$Z3X6B?4OLWEW"PW-AI-H]

MX39;2R,S@ DK@\UU9)3RJ,E]12E6C2BYVE5TLXW?OMQ=I=M^FB8LSK8^,U&O

M2Y*$M(OFIO=RMI%OSU-?]G#XB?ML^%_A_=:=^SWH'B75/ ;^)-1N[BZ

MTCX?:1XGMD\0266EQW\0U&\T:ZD$JVAZGXMMH-*UWPSX7\7:1!?^!O"L9:'4M,M'UK1KISHJRIJ5XO3[,KIG[*?"3XCZ1\6_AKX-^(VBE%LO%6A6>I

M/;K(LG]G7[)Y6JZ7*[email protected]=H_/WK9J^.Q>&G@\15P\]Z4Y13_F2DTI*W

M>WRV>J/H*%>&(HPJQ=N:*;6NCLFU\KGPU_P4 _:U\4_ 2'P1X/\ A?K.GZ;X

MYUZ:77-8N+C3;'5I=.\,VYELK.-;75+:>U5]0U$7)#F-Y%727"A1*&/LY!E7

MUYUZF(I\U&/-&"YK>\N1_9E%[2TZ;WUL>?F&81P[I4JKS^+=3ED\)6$>AZ+H8L/#VF,]D+Z1=(TZT

M:YEO]12ZD4S;U$-M;R1;1,G;V3:E[TG9QE)?:;VLOP9UX&

MO5K4E.IUVV[1?1+N?8ZP01G='#$C8QN1%5L JDP*TVI0J)'AO/LR/+"JVLA0Q>8\/T?#F8X3#U_J-6IR5ZLN>"Y9

MN[G*G3C&\8M+WENVDO0\'.Z4Y>S<5=+EZK^_W9^'%]8WNGW$MG>VUQ97,#F*

M>UNH);>Y@D'5)H)562%@".&5<5^@I::==CYJ47#1^Z^W_#%>"":9XXH8WE>6

M2..)(T+R2/*56-8E.=[,64 #N>:QJRC1A.55\D(IMO5V23;=E=Z)/8B$)2E&

M$5=R:26F[=DM=C^F[]AW]G>/X!?"&R_M>S6'Q_XX^R^(_&$CQ&*XL/-A5M*\

M-FVTS^:HZW=Y>G)4(%_.*?([TJ-X0?=1E.TK-1:T>SNU;?4^Q

MRW!_5J*ERVG*W,K[:1;UYFMUT/I_QOX<7Q+H5U:I>P1-YQN%Q&K?N5+

M,JKYRGR\M\H)#1HMMLH3/*-J(Q.#)G<54-MP&)Y QGI5)NZ%%J_

MPV[:G2_!G5;K7O'-T]L)#IVEZ;=&Z=4Q"KRLD-M#(S(/G=][KR2?LQ/0'%EH

M^2O^"M7_ "3?X4_]CIJW_IF%?4\*_P"^5?\ KU_[? ^>SW^'3_Z^+\IGA'[*

M?_)@/[7/_7QXC_\ 4+T&NS./^1_E?^*A_P"I$C# ?\BS&?\ <3_TU$\\_P""

M7WA#0?$W[1=]J>L6L5WK^)-"2:-)8[?6&U;0]"BO=DB%1+#9ZS?-$X

M(9)-CJ0R UV<25*E++;4Y.*J5XPG;K'DG+E]+QC>W:VS:.3(X1ECY.4;\D)2

MCY2YHQO\DW_P]C^B>OSX^S/Y@=6L;/2/V]6T[3+:&RL;7]J"VM[>UA15A@MU

M^)$+K!$A!"0J?NH,!1\J@+Q7Z5K/(7+XKX-MMO?_ &>[\]>Y\;%*&9S27+&.

M(E9=DJJ_(_1W_@K'Q\*_A?ST\?70_P#+?O"01WZ#K7S/#:_VJNN7F?L96UM]

MN!Z^;NU&CT3(5 /8+X;\'@ >P K'B"T

M,;27)ROV4>M_^7E2WI8K*-,+4_Z^2_\ 28'R+_P5FX^*_P +/^R>7/OC_BH]

M4)KW^%/=PN(Z+VM1+UY*)Y^=Z5J?3]S'_P!*J&7^V%Q^QO\ L5]./#EMUSCC

MPIHO4 @X^A%9Y/IGN;=+>W_]/P#&Z9;@?)T?_33/L+_@EAX3T+3_ (%>(/&-

MK9QCQ#XE\E7%?\ 8/4_]*@?.'[#

MO'[77PB]O$.N_IX7U^NC--,HETM2?_IF9SX#_D9O_KY_[EB?HU_P5I9D^''P

MJP=O_%::L>, @KHPQ@]1^&*^=X6$?6L>)M,PI^5%?^G:ITY'_ND_*K+_TB

MF;?_ 4(X%BB#7-[X7EB1?%%@A6)I',-O!;

M:DJ!@#_94B@%I14\.8[ZIC51F^6EBK0?937P/[VX_P#;WD5F^%]OAO:17OT+

MR7^'[2^2U^1\L?\ !+?X\6VF6?CGX,^*=3M[+3["VO?B#X5GO)8X4A@MH8E\

M7Z>K,H)2.WAM=35%8E5CU*7&-Q'I\2X*4ZM"O2CK+DI6NOBE*HT[N2MJTK6M

MKOH>7D^+Y/;4JKY5",YI6Z1Y$M4NU]+WT/C3Q-=Z]^VM^UVUOI3S+:>,O%::

M1I#R9N$\/^ =$61&O &6, 0Z!976H/& H:>X=!EY5SZ%-4LKR5RG^ZJNG=+5

MWJ.C>VG-%7E%Z[7]=>>:ECL?'W/=C-*+O]A5--/=>TNNI_3!XYR3R:_/:E:56K4J37O3

MFW?U=[VLK;['UU*E&C3C".G+;3T27=]C;I&@4 % !0 4 % !0 4 % !0 4 %

M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0

M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '"?$+P@

MGC'PU=:8K>1J4'^GZ-?*S1RV&K6R,;::*6-U:(-N>)V4Y"RD@94$>!Q)E?\

M:N58FC!?[3AZ=2MA7?;$PHU(T'9SA'XI[5&Z?\Z:1R8RE.MAI1@OWJB^75:2

M46ENTMWZ=]$?"EMKL^HWLFA?$'1M \6-IDLNG30>,/#FA>)+F,6UP\3PF[UG

M3[J5E5FF&P2A072"=.ONO0C"ZJ<9(SGWYKXNOXBYS2;4J?+9.WO4'W[89]B*F<8ND[*

M%E?5WAHM4W;DUT6R,_\ X:9\>D "P\,G*]#8:@ W/I7-2\2LU]

MK24HVCS13UI;75]L-V[$PSNIS03DDKI/W5M=?W#*A)*7-))Z6:U2BOY4NIXUXN\7RW$@L;(F2

M2:06\$$0+.\DC&-(E41Y+EG0 =>?2O>5.:>VWH=#ER[JUC[L^$'@0> O!]I8

MW2+_ &YJ*Q:EKTH*N?M\L2XLUD4D&"TC(A7:=I<2R*/WI);36G8:E%=;6/SH

M_P""M )^''PI"\D>--6X&,C&BYZ?13^5?5\)QE+&UE%7#_ +*OR?L!?M;J006N?$048)SGP9H(["NS-XR_MW+)

M)>[&5*[_ ,%=N7W)KUZ7,,"N7+<7%Z-JHTO+V<>QA?\ !*)&3X]^.205'_"I

MM4'Y>+_!V>/09'/N/6M^*%;+J73FKQDO\+IU;/\ X&_D24;^

M?/3=K;G] &0!Z ?7C'L*^!2VM\CZ]^ZF]E']#^8[Q.K?\/ +AA@J?VIK4@@@

M_?\ B/ J\ \'<0,=N]?I%*I"/#_L[VD\+R)6?Q?5K6VMOUV\SX^4)1S-W5O;

M5_O=/RKYWAI\N,K=/W32

M]?:0/5S=/V-&FE[T'%M=K*:>NVGD=G_P2P('[.GB &_!S=#

MTX8?G6'$G^_4FMHTXQ^:J5="LJ7)AZD7[KJ8' YZ=NG&>HS[W"[2P==;6K3E\N2EJ>=G,DZM.STC2C%

M^J=30S/VPE;_ (8Y_8L3:G9^S'@\'_ (6'XK..

MN,VNB8Z=#[=N]>/Q')3QU-Q=U&E%/U52IW/7RB$J>%DI+E?.Y=/AY(:Z7[;;

MGU#^T\&-3/IZ*?RKS]?:9]K'

M-;/$T&NFEJECYC+9Q@\35;M3^KU%>SW]R6RUV5]O+>@!\,:^!D]O3%=&9K_ (2II;QI._RHR,,!)+,(SO:$ZBY7WO5BUINK

MKO;S/TR_X*M>'-:U/X1>!-TNKDH?W-

ML]U"L/FN-HDEACR&F7/S7#5:G1Q53VDN7F@HQT;O)SA962?;?;NUH>[G.&K8

MBC3]C#F]G44Y:Q5HQC.[]YJ]KK1:]D?%G[)/[>6E_LV_#34?A]J?PZO_ !8U

MWXLU'Q+;ZG9>(K;251=1T[2;%[26WFTFZ)\M]*#B0.,^<1M&P%O9S#)O[6Q'

MUBEBE25->R:VW3M&^%KRVN)8);GP-XNM;ZQ-@\ZR[I8EL;G4=&N2Q

ME-M< C:YS^CX'%?VC@J%6JN;V;@IRO;]Y"$>;1*-[FG8^,QJC@L8X4UR1

ME'EMJ[1I

M6PY*+K^'

MY++5(I[/0XX+2X?46NY;%;26!8;ZU8^5:QDTU;US//?6L;:O8/'.OD>:Q21"%^<9T=):

M;;OW?,(8S#3YN2I?DBY/W9*T5:[UCY[;E%?VF_@2_P /H_BHGQ$TMO $NO+X

M7C\0K8ZV8FU]U#II8L1I?VW[28R'YMMNPA]VTYI?V?C/:SH>Q_>TX.I*//#2

M$9-PJBI^UM%RY4^67Q6O:W+?;KMYEVT_:+^"][I/Q UVW

M\=6/]E?"RYCL_']W-IVN6J^&[J6XGM(8+J*YTN.6XD>XMIHU%JD^YDP,Y&9E

M@,7"I2I.E:=:W(N:&M]%JI67S:''%X>2FXU+JFFY>[+1+?IK;RN-E_:.^"D'

MA;P;XT?Q[I[>&?B!K!T#P;J4.GZW(_%'ARY\

M366IVLNEZQ.^@6]E:Z-J307DTEM'I"I@YXQ1

MIN2A3FH.+4HKG;ZLEJ>*_'3]M#P+XPU"R\,M;6E_IWVR2%[\7-E'(^HIM>18MU=V-R_#X=9A&GE56*H07LZOM

MKQ@O>_>M.5VI6NHV;5O,YL+BZU3ZIS8ZFW4D^:'L[-_#[B:C9.-[-Z7N?I_K

MVO:+X6T74_$7B+5++1-"T:SGU#5=5U&XCM;&PLK9"\UQW*O7?A

M?X>?$'3M;U^TCGG72I;+5M'N[ZUM1F>[TN+6M/M#JEO&N69K;S2JJ78*H)KM

MQ65X_!4U5Q&'=.F[+FO&23Z*7*WROULU\4V^I_V+=Q-::NVD6.KB7[.VFWOB./3VTNUNDG!

MBD$EVJQ.K)*R,C!;AD^93H+$PPLG2<>9:QYG'?F4+\S5M=M5L2\PP.?VD_@=\-->U+POXZ^(FC>&]?TG0D\27>EW\6HK/\

MV3*0L$MJ\5D\5]=3,0(K.VDEN9#]R$X.,J&6X[$TXU:&&E4IRGR*2M;F6Z>M

MTEU;LEW+JXW"T)RIU:T83C'F:=]NG37R2U\CSR;]N7]ENW\*V'C"3XJZ;_9.

MHZG=Z1;6\>DZ_)K8O;%+>6[%QX>CTIM1M;:.*[MF^U36R0-YRA)&;('0LCS1

MU945A)CT3OIL9/,\#&FJGMTHR;25IN:?::KI&IV;^9:WVGWT*7%K

C36C7R.V$HSC&6M3Q$(_#)2GK\*3E*6[UMY:OMWX;P[JMNS*S!25Z@@B-% Z#D&OG\!

MBJ>(PD:?FCSC8T;X(*A"1UY

M 7:>"#GCVKY:$)\Z45K%J^W1V]#RW&3^KQBO=3:T3W:BNMM#WQ?

MLS_#V;Q1XFF\R4VJC7-RNZ>NZU3LGY]58^]K_7=$TF6*WU/6-,TV

M:="\,5_?VMI)*BMM+QK<2H67=QD9YX[5/,]G"R>^O3J:V_ S/$/ASP;XK%EI

MWBG0_#7B,)YMYIUCK^FZ9JZJ51(Y[FTMM0AE Q'-&&DC7HZ9."*NFI4KSHR<

M+KE;7\NCMZ:+\C.K3A4BHR5TI72\[->71LS]/\*_#?2O#FI6&F>'/!.F>$]2

M%Q)K%G8Z3H=EX>U!%"VES)J4%O EG=J%@$+M,&&(=CF>%?AGX#+ZYHWAKP+X.\^!;5]8TW2-!\/F>WN'CF6

MV:_MK>#S(9&@BD$9SCI:^EK6V]-/30RE1@VJGLTY

MP::=]FM5Y:,U=;T#P;XO)TGQ%HOASQ,=+DBNCIVM:=IVM#3I;F)D@G^S7T,P

MM))(=VUMJEER1D9J8WI*7LGRRE?\?7I=+38B&[;PKX>F:5[N3P_H<5 m>UU::UNM/DNQI",*:4::Y;:+??YF/XET3X5^(=4@B\8:/X UK6K:..RMHO$N

MG^'=1U2&*=_,BM($U2*2>.*267%O!5_HWA552TTW4M&T*ZTWPZJV\>U8+2ZMVATI

M1:K%]U8_W87^'%)2KQ;DJSO*]]%UW*E3@X1IM^[&UEKT5EZ$M@_P^\#Q/H>F

MMX-\(0+-]MDT>Q?1/#\0FN0F;M]/MS OF2HD?[TQY1TMW'I.L0:AHMXFGZI!/9>3J>DW'V:\BFL-0CEC$5_8R;UDL[F)9D

MV2H4E42+AAN%$93C*+Y>7E:UOM9[Z=B914XN#>DDT].C5MCCO"GAOX7:5>7T

MG@G0/ &GWXM_L>J/X5TOP[:WGV5I 3:W[:1 LA@,T7^KE^4M'TRM;3K5)\O-

M5FU%IJ[D]KVM?:U]+;$4X1I+DCK%:;6[+SZ(71_AU\+=*U87F@^!O >G:[H\

MB2"[TGPUH%IJFF37,,FQQ/9V2SVDDL,DA'S*75R>0"YMIXG#Q

M3!94>-T8'YD*D9%'-.FXNG=2BTTT[-?/H*UTXMZ/1Z?(\*3]GO\ 9>UF_O?)

M^$7P:U/4EEDFOTM_"GA2[N8IC)MD:YAAM&,)\W((95^;/&KT6IF\)A9-'X-&MO#K:5:Q6L=L-(NU,!BU!0BH(E06X0#!^

M7NR[*O[2C*;JN-Y6>G,_LMMMRB[OF_KIS8S'/!M0ITKQ2WYDK?$MN5[**>GH

M?B1XZ\8_$3]M_P#:)TIK72FM-0\476E^&?#NAV[R7=CX4\+VLKM++//((1+;

MVD4VH:A>7)6'S&>[Y=_FY

MUZF.QL%[/F4I1BWS)67/;:T7HF?TO?#SP1HGPT\#^%O 7AV(0:-X3T6PT:RR

M,+.!$FNYMSN?M-S<>;<2G

([71M7MM-NGE\Q0MPESK/AS8496Q;J!D*6Y/!8G!1I

M-V^K8M5FEIRTX1@W+I=:M6UD];+MX6818(_$=]9OO167%DI.&

M4!/2[OHHW3::L[.[T7G.56,L-A8+2=2G.2TV

M?NMW?E;1->5MSZ!_; OS\!?C=\6;71K(0:?\=/V==*\'Z3#"C(J7D>I>'?"\

MT"'[6))I4T#PQ.@53N9[V,.CH"6YL!_MN7JM)\U;#XF59^2A"]^BLG+1:NUM

M&C;$3^J8F4+\L:E+D77WG+1:7MMOHO0\UB\/-I7Q%\/?L6N99--M?VI?"_C:

MZ1DN"LF@7?@W2OML 5;Q7^SQV,D[DX&[S$D#G8*ZO8_NL5F$?A^I58E^A,&Y*A23U]O!M>3LGY?J=C^T,9O 'Q\_:*^"UI&8+/]I36?@K

M=:9L_=Y:[\4V%WJQB)N]T:/J,^NPN54J?,(\L;5*X8&$<7@%BVVI82G+S]ZE

M3T[7NGS7L][-O5%UI_5L1*@W95FX)6WYY66U[7M;=6[]2C\++-M;^/GP7_9C

MFA\K2O@/^T)\9O$LL3Q7)0:)H5[9>(_#Q;S;L-AI]'U:/>8\;+V-D:3Y\QC*

M7L,(\8M%CFKJPE-*VK7-Z)=K=51E>I"D]%AZZJ-=HTVDWYV[)M^3/I'

M_@HO\0?!7Q)_9V\":_X#\2:9XIT6V^.VDZ1/J.DS&>VBU*R\)^*WN;-G95(F

MC2>%B,=)5(/-CU.K-JM.MA*4J4N:,

M:Z3=FM5"3ZI=T3>'=$T;7/\ @I=\0+?6M)TW6(+7X)Z7=V\&IV-M?PP77_")

M>!;3[1%%=1NB3?9;NZBW@9V7$BYPYR59SI\-8?V"1K+XN^&WLV>*-VLW

M>\\#0.]J64FW=H6:,M'M)5BIX.*]?$MKB'+;-J]"5_NJ/7YGGT4O[(QFGPU8

MV\M8+Y'L4UI:VGCO_@EY]EMK>V\_PEX3NI_(ACA\ZYFN?#K37$WEJ/,G\">(M.UR]\(?$#P;H'Q.L-.F\RY\.0R:G?&"TU-24,+OK^EV4.!YF3&Z

MD8R5\WA[#5*.98:I7I.$:U*I*BY+2?NJ[CZ1;9V9M6A/!UH4IJ3I5(1J);QU

M>C[>\D=-;V?[/^E^//V33-;ZO9?&)_A/8K\+8_"L7D^'[G3#X6F:==?^PJ$E

ML7$VHE#*VQA),6."YK*^82P^;-%

M+^QZ[DE[3ZPK][^[\]K_ (GT/X1TLZQ^WI^SW:^,M.L]3U ?LX^#[C5[74[2

MUO81K=O\)]:EGF>"1'A\^*_5G5E!"NH9", UY]67)D&8.C)QBL9447%M>ZZ\

M4E?>S1V4X\V:X55$FUAX732^)4GTVT9Y;\-O#GAY_P!G_P#X*#7[Z%H[WVF^

M*9;33;Q],LVN=.M;?7-7E@MK&9H2]G!'(JLJ0E%!52!\HQU8FI4681^J7[%))_98^"V221X4=

M1N))"IJ^IJHR>RJ .P Z5\KG6F:8W_ *^?^VQ/=RW_ ''#?X/U9]25Y9W"

M'H1[?3]:'MV#;Y=#'US1K/7M(O\ 1M0B,UE?VTMO.A8A@'0J)(WW966-MKHP

M/RNBL.1FO,S++X9C@<3@:L>:->G4BG=JTITY4UHI1V4F_B2]-U,X1JTITY*W

M-%QLO-6Z6[GY\ZEX6\0_#OQ!-IFI0W2V+SM_9NH;6:SOX'?]TT4P#)YAB4%X

MBQ9#E6'&3_/^*R?'\/9I4H5J7L\/*-,R+&^XYQA0N_."0!

MU/'6NS$P^L4%"UZEK);:\K5NBW9BG?:^VIY-:E-

M-SY?=CJW=;*[>E[Z+L7?@#X(\1>)OB'H5]86%R=-TG44U#5-4>/&GP)!D-;3

MRR I)),S"(VZ'S&5W(7",5_3>'L)4CCL).G"]"C*D[W7V*E-[-\WP_Y:LZEQJMKIT&UG5

M"K7-T[&2YNI0229)9F=N2AY[XT\&:OX

MG\>+Y L[329_A]?Z1-EI?T*4X);VMTLQE[X*UZR\2?#BR\/ZK?V%CX;\':]HUQKTUE::DS%6

M\-6]M#=I=((UN+FWLYI Z@8-L0 1G.\?9.,E)\O+K%:ZO1)75K>ZV[O32W5&

M5:QR-MX4\87?PO\$> O[.DCN-0U_59O$LFI

MK=6UI#HVFZ]JVN+!J9M&\VV_M.;^SXU6(JQCF=5(' 7[M;=-M]_T^9:JM=4F

M_1;?+0N7?AOQMJ?@'P?X6N[>:#7/#'C[1],N-2;3X]1M)='T:>X6R\2+;W95

M+W3_ .S7M2PDP2Z2(V'4D2Y735K7T] =1ZKRL_3[A(/ 6L/X%\$Y+O4[2QLE6"WCBM(+EI/)9P&M)&+9R*M>SBHZ

MZQ79[JUO(SYVO*VQ#X+T/Q]_PL71_$WBJTU!(M,\*:OX59D026\HT,:(L.H-

MY>Y?,U74)]9FB'RLT3ZS;^(+"&.[DU+1[6X5KOPQ)JL3#RX4L;?38K,F/;M;4SYO(J3070],FLI

MK3PSJOP^O]7\41>.KC6[KQ4UK+;:=)9OKUQ?V_BA?$T6U1+#IDD,::4)-[-"

M+9HA S$ ?@68]+U6S^)_BN^GL=;33]1\1^';FR>#P;::S8WMO;:'HUK+(=:]\8O[,AFLY/$'@+P[I/A[46S!;RZI!8^+(76"?&%>"6]L]Q'

MW/-4T+2WD'X6*?@D::VHZ#)IGPQU/PY-X:\*W=CJNJWVE2Z'+;W'E62KH.G0

MQ;$\4&:>":8SDR0Q^4LB2>;G4:TMTL8G@'0?'6A>+K+Q5J^F*EOX_75G

M\306OVR2\TBZE9]7\/-JL,^5MQ96H?2LQ#:#*!(2VW"V+;5K;6V.N^&USJ&F

M:5>^';_P]X@@U!=;\::@DUWI]Q;Z5<0WWB'5-2L0NK,GEYGMKJ':5!(W'*[E

M(IW^5C/D2^UMY'!_#+1M1TWQ5H-I#X;UZUL-*TC6;>^E\2:#;:;>>&VGDCEA

ML+3Q-IWV:#QG!7[.)6@A+[,;O*3/W16M'

M%XG"IPH/EB]_A?EM)/LC&>'A4DG-7Y?7]&NX[PI\-/A]X!:X;P/X&\)^$7O

M$O)/#F@:5HTER@*D)/)86T33("B$*Q(!4'&:=7%8BNH^UJ-\MM+))6\DDM+[

MVN52P]"DW*,.5ZV=Y?JV=KL/I^O_ ->L;O\ F_ WNNP!,$<="._I^-%W_-^

MKKL2TA!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4

M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %&WR#;Y'BWQ@^ 'PL^

M.UOH=I\3O#;^((/#"8-)MO#NK+JFJ0QVD6B3W,^EB738;M+.\DMY+N9DDN+>5URF&

M'E1[-5F&*C1J8=22IU7)R7+'>:M+7EOMV:\C%X2DJ].K%6]G&*6^\9777I^(

M_P")_P"SK\)?C#K_ (5\3_$#PR^M:SX,??H%TFK:MIWV;_3;?4!'/%IE[;I>

M1"\M89 DXD'WUP%ED#S1QV)PL)4J,N6$KW5H]4D_B3:T2V'6P=&O*,IK6+76

M71MK9KN/F_9Z^$\WQ=@^.C^%4/Q,M[<6T>NC4M3$.%TEM#29M)-W]@:[72F^

MSK'A.,U'

ME<6FOBW6VG-89XR_9W^$OC[XC>$OBSXH\+M?^._!#:4_A[5TU;5;1;9]#U.7

M6-*:>PL[Z*TOFM]0GDD4W,,N1A&RBJH5+'XJA0J8:G/EI5)2NK1VE'E>K3:T

M72S3ZCK82A5J1J27O0::=Y+9MK2Z6['Z/^SU\*- ^*6M?&?2?#'V3XB>(8+N

MWU365U35989DOXK:"\>/2YKUK"VGFBM(@\T-LDA)E.[,TGF.>/Q-2E3H3DG3

MH\O(K17P+ECLD]%YD1P=&$Y3BK.5T]9;-W:^(Y"7]C_X!7'P^@^%TW@RX/@J

MU\:R_$"#2AXD\2JZ>*9;&337U#[?_:YNC']BD>(6QF,(&,1@BKHYEBL-5]M1

MJ$N=1Y8_%=N][7WD]+V-5A:,:[Q*C:M*/*W=[))

M6M>W1=#B-+_9,^!.C?#?Q5\)=/\ "-Q!X$\9ZQ;:]XBT@^(?$,DE[JEG+836

M]PNHRZFUW:A)-,LCYZV1LR?LU_!^34?A/JC^&K@WOP1L;/3?AO)

M_;NN!=#M+ VK6L^'E[/7"I*GJ_=2M;KKMUN3P_LY?!Z)/BO#)X1BN[?XV7O\

M:/Q(MK_4-3O;?7+U9[VZBN88;B\==)EANK^XGB:P%L8I?+DC*O$C*GF.,_V2

MU;E>!7+1:23@M%:Z7O:))\U[K3JQK!X=>W7L[K$N]1-MW>O=Z6;NK6L,/!WAW46\26NG2:/I>J>(/$.L>(9M#TN57CEL=%CU.[DCT^)H

M7>+8(Y)(PX2617TQ6;8[&4O8UJD53NI.,(1AS26SERI.36^O77HC.AE^&

MPL_:4H/G2LG*3ERKM&[T^1@ZE^Q#^SAJOC2Y\<7?@>7[;>Z[%XEO]#@US6+;

MPC>Z[%(\RZA(K+('TCG>94Z"H1KKEC'D4G&+J

M*&W*IM9J'-W]K%[F#0/BY>R:AX\LSK^O2/JUW)--.\D-U)J+3:8/-N)6"V:YI:O[]/E8]

M4\"^"/#?PW\):'X'\(6+Z;X;\-VAL=(L9+JZOGMK8S2W!1KN]FEGG/FS2'=)

M(Q^;&< 5R5Z]3$U9UJLN:I-WD[):VMLK);=#>E2A0IPI4URPIJT5J[+U>IUE

M9&@4 !Z4;>5@6GE8B:(, "%(!SM*AN1]>]#4=+J[CM\MAMIJSCS?.P>4H&W8

MF ,8VKP/3I3T6VZV)22^Q:Q$]I;2*4DMH&1E*LK11LK*1@JRD888SUS4WDEW

M\AM1:<>C37Z$J1)$H2-%15.0JJ% /K@=Z%>VW+;H3"*IJT=%VV_K8DQ_G H]

MXL3;[D8QTXZ=. :/>7R] T^X,?AC\.G2B\E\@V^08Q^'Z8X%%Y?=Z!>WR#'^

M?3'M1>2^0:+Y"!,>HXQU/&.G>B\E\O0-%\A0,?AC\,=..U%Y?< [_/Y4Q!T_

M#^E ./\YZ_6@ Z?A0 4 % !0 A /'/X$CMCJ#0 ?YSC XSTX':@ P,@X

MY'3VQZ>E "T % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4

M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !

M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4

M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0

M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %

M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0

M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 (3@$] !GZ8H ;YBX

MXW$#T1VQCZ*>: &F:-02=ZA1GF*48 ]ME $7VRWP3O8!?6*48P,]"E ##J-F

M!_K2 /\ IE-QC_MG0ET#;Y$1U?3TZSE%@/^0H !SS9Z@ /^W2A8>KMR?C'_,",^/O"*@G

M^V(P%&?^/6_X ^EK5?5:_P#S[_\ )H_Y@1'XB>#0/^0U& .?^/34.,?]NE'U

M6O\ \^__ ":/^8$9^)[email protected] S_P >6I'@?2S]J/JM=?\ +O\ \FC_ )AL

M1'XH>!$ZZ_&,#/\ QXZH< ?2Q]J/JM=?\N[6_O1_S A/Q7^'Z]?$,8P,_P#(

M/U8\#_MPJ?85?Y/Q7^8##\7/AVH)_P"$DB 49_Y!^K< >WV"A8>MHE#TUC_F

M!$?C%\-U!/\ PDT0"C/_ "#M8X ]O[.J_J>(7_+NUO[T?_D@V\K$?_"Y_AF/

M^9HB '_4,UH8Q_W#:/J>(7_+O;^]'_Y(",_&SX7KU\51# S_ ,@S6SP/IIE'

MU/$+_EW;_MZ/_P D&WD1'XY?"M.OBR) /8:71]0Q7_/K_P FA_\ )!>WE8C_ .&@_@[@G_A-

M;4!?72]>&,#/0Z51]0Q2_P"77_DT/_DB>>*Z_F1G]HCX,@?\CO:@#G_D%Z_Q

MC_N%4_J&+7_+K;^]#_Y(.>/?\R,_M'?!5.OCFU&!G_D$^(3P/II'M2^H8K_G

MU_Y-#_Y(.>/?8B/[2GP17KX[M1@9_P"01XB/3Z:/1]0Q2_Y=?^30_P#D@YX]

M_P QG_#3'P.'_,^VHQ_U!_$?&/\ N#T?4<5_SZ_\FA_\D'/'O^8P_M.? M02

M?'UJ H)/_$F\2G ')_Y@U-8#%[>R_P#)H?\ R0N>*ZVMY,A_X:D^ H_YJ#:\

M?]03Q/V_[@E5_9N-7_+G;^_3_P#DB?;4_P";\'_D,/[5'P"4G_P#)A[:DOM6MY/\ R(Q^UM^SQC/_ LFQP/^H'XI

M&,>QT*C^R*N,?]

MP*C^R4O\AI_;"_9N4$_\+/T\!1G_D!^*^ /

M^X#1_9.8?] __D]/_P"3#ZS0_G_"7^1%_P -D?LU#_FJ.GC'_4"\6\8_[@%'

M]DY@O^8?;_IY3_\ DP^LT5]O;RE_D-/[9?[-"@D_%*P 49/_ !(/%W '7_F7

MZ%E.8;?5_P#R>G_\F'UF@OMVM_=E_D0_\-I?LQC_ )JKIXQ_U+_C 8Q_W+U5

M_8^8K_F&V_Z>4O\ Y,CZYAE_R\LE_=E_\B,/[:W[+ZCGXKZQ

M\/5/]DY@O^8>W_;]/_Y,7U["?\_?_)9__(D?_#;?[+8'_)6=- '_ % /&'&/

M^Y=H_LG,/^@?_P GI_\ R8?7L+_S]_\ )9__ "(W_AM_]ED?\U;TT8_ZE_QB

M,8_[EVFLHS#1+#^G[RE_\F+Z_A%_R]M;^[/_ .1&']N+]E903_PMS3 %&?\

MD7_&/&/8>':K^Q\9C&!D\?\(YZ4UDF9[?5O_*E+_P"6 LQP>RK?^23_ /D2(_MV

M?LGJ"?\ A?[)7_ $6/3/\ PG/&W_S,T?V%FO\ T"_^5*/_ ,L#^U,!

M_P __P#R2I_\@'_#>?[)7_18],_\)SQM_P#,S1_86:_] O\ Y4H__+ _M3 ?

M\_\ _P DJ?\ R ?\-Y_LE?\ 18],_P#"?[)7_ $6/3/\ PG/&W_S,T?V%FO\ T"_^5*/_

M ,L#^U,!_P __P#R2I_\@'_#>?[)7_18],_\)SQM_P#,S1_86:_] O\ Y4H_

M_+ _M3 ?\_\ _P DJ?\ R ?\-Y_LE?\ 18],_P#"?[)7_ $6/3/\ PG/&W_S,T?V%FO\

MT"_^5*/_ ,L#^U,!_P __P#R2I_\@'_#>?[)7_18],_\)SQM_P#,S1_86:_]

M O\ Y4H__+ _M3 ?\_\ _P DJ?\ R ?\-Y_LE?\ 18],_P#"?[)7_18],_\)SQM_P#,S5?Z

MOYNO^83;_I[1_P#E@?VK@%_R_P!O[E3_ .0/=?AC\7/AU\9= N_$_P ,_$L'

MBG0;#5[C0;O4+>RU2P2'5K6RT_4)[,PZM8VLS,EGJEA)O6-D(N Q96"^?B<

M)B,%45+$4_9S<>9+FC+2[2=XN2WBUO?0Z*&*P^(@YT:G-"+Y6[2CJDG:TDGL

MUY'H]-248QQ+:>_K9'FCVLUY6#;RL0?\ "MM"

MP5^UZN >,">S'7CH+&CVLU\@V^1"WPNT HP-YK&"I!Q<6@X(P>MB>WL::JR3

M72P;?(I?\*C\-N#_ *9K2CH1]IL/Q_YAGH:T>(J1[?6GD/]"N_P3\+$X_M#7P,8.+G3@

MGH5-9A6MT5O(-OD5G_9?\!,0/[7\78QCC4-&&.O0'0#S2_M&MV7X?Y!^A"_[

M*WP^;_F,^,NF,?;]#/KV_P"$>JEF->+2LNG0-O*Q7/[*?PZ'R'6?&B[N/DO]

M!4#/'?P[UK7^T<1_=5O(6B\K#&_9(^'.TC^W/&_0C_D(Z!Z?]BU0LQQ"_ET_

MNB>D7Y)E0_L@?#9QSKOCE>-N%U+0 ,?CX9Z\T_[0Q']U6\C!)>EB(_L.\8Q_P A30?_ )FJ/[0Q"_ET\AV2[Z%5OV,?A>Y'_$^\?*, 875/#P'7

M_:\+L^( XQ_R%O#PQU_ZE:A9CB%_+I_

M=_X(VDFD1']B/X4@'_BH?B$..VJ^'/Z^%#1_:.(_NZ>0^5+Y$!_8@^%# I_P

MD7Q$PPV_\A7PV.O'7_A%*%F.(5OAT\B4E=+H0G]A/X2;3_Q47Q% P>FL>&P1

MQV_XI&K6:8G^[_X#_P $U5&FN^G]=RO_ ,,'_")AC_A)/B.!TP=5\+G]3X/J

MGFF*7\JM_=_X(_8P7R&']@?X/X(_X2/XCKP1QJOA?(XZC/@_J*7]K8I=8Z?W

M4+V,.WXO_,@_X8!^#Q&/^$G^)>",$#5?"8X/!_YDL]O>C^UL7WBK?W4)T86:

MVT(F_P"">_P88$?\))\2QQC_ )#'A48_\LRC^UL6NL=/[IC]7@OD0'_@GC\%

M\8/BCXH $8PNM>%5Q_T)?6C^UL7T<5;^Z@^KP7E8B/_!.OX)X(_P"$H^*0

MXQ_R'/"QQV_Z$RC^UL6NL=/[J#ZO!=]/Z[D!_P""C^UL6

MNL-/[J#V$%\BN?\ @F]\#B-I\5?%< C!QKOA(8!X/_,CTUFV+36L=/[HG0A9

M^A%_P[3^!)&/^$K^+(SQD:]X1XSQW\#5HLYQJ_DT_N_\$R6&IW2U_KYC#_P3

M,^!."#XM^+1&"#_Q//!Q..AP3X#I_P!O8Y?\^]/[O_!+^HTE\O7_ #(3_P $

MQO@(1C_A+?BX,C'_ "'?!G&>/^A"H_M['+_GVK?W?^"/ZC17?3U_S(C_ ,$O

M_@(5(/B_XNX(((_MSP6.",'D> >*/[>QJZ4U;^Z2\#2L_3S_ ,RJ?^"7'P (

M_P"1O^+ZX&.->\%G&._S> #2_P!8\ W%;^ZC)9?12W>GK_ /)$3?\ !+/X

M ,"#XQ^,.",?\A[P2.#QV^'M"XBQZ:^#1K[*%_9U)Z7M?3K_ )D!_P""5/[/

MA!_XK'XQ*,$$#7_!73'/)^'W'%;+B/,/^G?_ (")911T]]_34+-/^AR^,O\

MX/\ P1_\[ZC_ %CQ_P#T[_\ 0_L+#_SO[G_ /)A_P .HOV>/^AR^,O_ (/_

M 1_\[ZC_6/'_P#3O_P$/["P_P#._N?_ ,F'_#J+]GC_ *'+XR_^#_P1_P#.

M^H_UCQ__ $[_ / 0_L+#_P [^Y__ "8?\.HOV>/^AR^,O_@_\$?_ #OJ/]8\

M?_T[_P# 0_L+#_SO[G_\F'_#J+]GC_H/\

MH/^AR^,O\ X/\ P1_\

M[ZC_ %CQ_P#T[_\ 0_L+#_SO[G_ /)A_P .HOV>/^AR^,O_ (/_ 1_\[ZC

M_6/'_P#3O_P$/["P_P#._N?_ ,F'_#J+]GC_ *'+XR_^#_P1_P#.^H_UCQ__

M $[_ / 0_L+#_P [^Y__ "8?\.HOV>/^AR^,O_@_\$?_ #OJ/]8\?_T[_P#

M0_L+#_SO[G_\F'_#J+]GC_H/\ J/\ @CM_W3ZA<1Y@FOX>G]T/["P_\[^Y_P#R

M8#_@E%^SN/\ F-GSOW>EGT_[

M?/L3]GS]GWP;^S9X,U/P+X%U/Q-JFD:IXGO?%EQ<>*KS2K[4$U&^TK1='EAA

METC1M-A6R6VT*T94:!W#R3$R%658_(QF,JX^K&K74>>,%%T;VOT2ZM]D?_9

end5>77w>

XML

infi-20200730_htm.xml

IDEA: XBRL DOCUMENT

0001113148

2020-07-30

false

0001113148

8-K

2020-07-30

Infinity Pharmaceuticals, Inc.

000-31141

33-0655706

1100 Massachusetts Avenue

Floor 4

Cambridge

02138

617

453-1000

false

Common Stock, $0.001 par value

INFI

NASDAQ

false

XML

R1.htm

IDEA: XBRL DOCUMENT

v3.20.2

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Section 14a

-Number 240

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

EXCEL

Financial_Report.xlsx

IDEA: XBRL DOCUMENT

begin 644 Financial_Report.xlsx

M4$L#!!0 ( &:8_E '04UB@0 +$ 0 9&]C4')OQLOD&1#LD)^OCG!CVX>;QA&WPIG

M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQJ=0U[R;UEA_6\#MI7E!+ P04

M " !FF/Y0!+-;->T K @ $0 &1O8U!R;W!S+V-O&ULS9+!

M2L0P$(9?17)O)VE!,71S43PI""XHWD(RNQMLTI",M/OVIG6WB^@#>,S,GV^^

M@>E,E&9(^)R&B(D25M-&F9@%5S18Z ,HA; U#PQ

M'J>^@PM@AA$FG[\+:%?B4OT3NW2 G9)3=FMJ',=Z;)=&PO=&AE

M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?

MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@

MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1

MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP

M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=

MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP

M=M;,[email protected]=90:V1V[W4%[R:0S>IU].LYKE']I

MJP&G[;N;SY/\3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ

MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A

M6$G:A/@01AKBG'/FE1M'V5;SOX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:

MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_

M+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT

ML@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3

M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'

M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\

M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^

M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?!

M8/+]U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83

M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'

M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5

MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @

M9IC^4*Q3>UU$! UA !@ !X;"]W;W)KM'.)+%E V%W"#.$)%NZFRP-M#O33B^$+8,FMN1*^!%^[#;75AP(NSG(KTBH7]! C_P

M_QGN 4&%$5080:D78ACDC_'26 T3]22Q3;G33W$

MPP>7GQ"(;@71/0]BQK50,;F7,8%Y:N3!E0XC_MV[=RUCWJO8>JCBO;3";LDS

M7PDWZ@#YQ+)&,EQG*A,AG=)LS6"=1+RP(F*IN2!3&5TAH/T*M'\.**@IG2O-

MW'*^(',+XTB4)A-52*NW$:ON]?

MAI1V*Q+5 ?:$VLA$-EYNP;*E%O$+'KC9V&GP37+5L

M9UJ]"ADU3G:+YN,80ZL+!,4M_M]H,V4L2\GO(C_I)2V*?D## <96UPV*VWTY

MAV/89YU&P07Z]!H#J8L$Q=W]LP(O!VM7$K.V%I%N+[R$%8I5+5I7 XH[]E/5>IB(05?PCI\(Y]X\_C@4N#PE-*0=AMK

MH'=T2G4G_D?FIL60E">@YE]=@[C>':)W#:OR\N"Z5!:.P>7MFC.P"?&.PM7_\H8_0U02P,$% @ 9IC^4(.II0/4 0 ,@8 T !X;"]S

M='EL97,N>&ULU57;BM1 $/V5IC_ GD1V04D"*BP(*@L[#[YVDDK2T#J3YV^3M;C).&I T R*JG[G':(]BUC?=6!XOTK8T'[

M3&.5&;0F-,39476&+TSKVDD

M?"E70"Y.;E,;5X+8V"5VI(I/0!#M.M%WXHK$L)!&-\D$M>&LTGSVL(Y; RU8@Y5/8

MPJ_-E?;8D+@7'^NP#21,=0V]H26,,A$$_:-:U#[(WOV1++'B8O#]X&>C9_QM

M, B/#AHQSGALMOZWU)/;ZMQ:.;V3HM4*XMQ_N6&1\74PQ6]

MNJ ;2\)#F-,OX7V5NP=2#D*BT OJ1%V#?G%/O3SRTC_@5_J^OH:Q+/6S*G

M>_P9:C&H-UO58UB7I6J//X7W*+F?&^[_$L4/4$L#!!0 ( &:8_E"7BKL<

MP !," + 7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$

M^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+-8?20$3;8T.P6BP^0"X99K>]9!:G%C:^?VZH:TE[VE-S9NMQ=%A?BTX'H

ME'QY%V)N:I%FGJ:QJ,';>$X1+_)UW,#ECQ ,ZE._CR#

M+@^H%7I")\!K*_#,U#88CIV,IDAO8O0]C.=0XIS_4R-5%1:PIJ+U$&3HDO\P>=0>6N=6RKV'5[+E&''\GN4/4$L#!!0 ( &:8_E D'INB

MK0 /@! : >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,

MA:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@

MMO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*<

M//Y#='7=:7PX_;(X\ \PO%WHJ45D*4H5&N1,PFBV-L%2XLM,EJ*H,AF**I9P

M6B#BR2!M:59]L$].M.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04 " !FF/Y0

M99!YDAD! #/ P $P %M#;VYT96YT7U1YO,^>EZS>CQ&P

MZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0P1-XJBA[E.O5

M,[1R;ZEXZ7D;3?!-FI6.5Z*U .EK >MKBRAE#VQH%.JB]XY8:8P*I

ML0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D(TADIJ]X(;+U

M[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_

M 5!+ 0(4 Q0 ( &:8_E '04UB@0 +$ 0 " 0

M !D;V-0&UL4$L! A0#% @ 9IC^4 2S6S7M *P(

M !$ ( !KP &1O8U!R;W!S+V-O&UL4$L! A0#%

M @ 9IC^4)E&PO=V]R:W-H965T&UL4$L! A0#%

M @ 9IC^4(.II0/4 0 ,@8 T ( !A@P 'AL+W-T>6QE

M&PO=V]R:V)O;VLN>&UL4$L! A0#% @

M9IC^4"0>FZ*M ^ $ !H ( !SA 'AL+U]R96QS+W=O

M9(9 0 SP, !,

M ( !LQ$ %M#;VYT96YT7U1Y

XML

Show.js

IDEA: XBRL DOCUMENT

// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.

var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);

e.removeAttribute('id');a.parentNode.appendChild(e)}}

if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}

e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}

XML

report.css

IDEA: XBRL DOCUMENT

/* Updated 2009-11-04 */

/* v2.2.0.24 */

/* DefRef Styles */

..report table.authRefData{

background-color: #def;

border: 2px solid #2F4497;

font-size: 1em;

position: absolute;

}

..report table.authRefData a {

display: block;

font-weight: bold;

}

..report table.authRefData p {

margin-top: 0px;

}

..report table.authRefData .hide {

background-color: #2F4497;

padding: 1px 3px 0px 0px;

text-align: right;

}

..report table.authRefData .hide a:hover {

background-color: #2F4497;

}

..report table.authRefData .body {

height: 150px;

overflow: auto;

width: 400px;

}

..report table.authRefData table{

font-size: 1em;

}

/* Report Styles */

..pl a, .pl a:visited {

color: black;

text-decoration: none;

}

/* table */

..report {

background-color: white;

border: 2px solid #acf;

clear: both;

color: black;

font: normal 8pt Helvetica, Arial, san-serif;

margin-bottom: 2em;

}

..report hr {

border: 1px solid #acf;

}

/* Top labels */

..report th {

background-color: #acf;

color: black;

font-weight: bold;

text-align: center;

}

..report th.void{

background-color: transparent;

color: #000000;

font: bold 10pt Helvetica, Arial, san-serif;

text-align: left;

}

..report .pl {

text-align: left;

vertical-align: top;

white-space: normal;

width: 200px;

white-space: normal; /* word-wrap: break-word; */

}

..report td.pl a.a {

cursor: pointer;

display: block;

width: 200px;

overflow: hidden;

}

..report td.pl div.a {

width: 200px;

}

..report td.pl a:hover {

background-color: #ffc;

}

/* Header rows... */

..report tr.rh {

background-color: #acf;

color: black;

font-weight: bold;

}

/* Calendars... */

..report .rc {

background-color: #f0f0f0;

}

/* Even rows... */

..report .re, .report .reu {

background-color: #def;

}

..report .reu td {

border-bottom: 1px solid black;

}

/* Odd rows... */

..report .ro, .report .rou {

background-color: white;

}

..report .rou td {

border-bottom: 1px solid black;

}

..report .rou table td, .report .reu table td {

border-bottom: 0px solid black;

}

/* styles for footnote marker */

..report .fn {

white-space: nowrap;

}

/* styles for numeric types */

..report .num, .report .nump {

text-align: right;

white-space: nowrap;

}

..report .nump {

padding-left: 2em;

}

..report .nump {

padding: 0px 0.4em 0px 2em;

}

/* styles for text types */

..report .text {

text-align: left;

white-space: normal;

}

..report .text .big {

margin-bottom: 1em;

width: 17em;

}

..report .text .more {

display: none;

}

..report .text .note {

font-style: italic;

font-weight: bold;

}

..report .text .small {

width: 10em;

}

..report sup {

font-style: italic;

}

..report .outerFootnotes {

font-size: 1em;

}

XML

FilingSummary.xml

IDEA: XBRL DOCUMENT

3.20.2

html

false

R1.htm

0001001 - Document - Cover

Sheet

http://www.infi.com/role/Cover

Cover

false

All Reports

Book

All Reports

infi-20200730.htm

infi-20200730.xsd

infi-20200730_cal.xml

infi-20200730_def.xml

infi-20200730_lab.xml

infi-20200730_pre.xml

pressrelease2020q210q.htm

http://xbrl.sec.gov/dei/2019-01-31

true

JSON

MetaLinks.json

IDEA: XBRL DOCUMENT

{

"instance": {

"infi-20200730.htm": {

"axisCustom": 0,

"axisStandard": 0,

"contextCount": 1,

"dts": {

"calculationLink": {

"local": [

"infi-20200730_cal.xml"

]

"definitionLink": {

"local": [

"infi-20200730_def.xml"

]

"inline": {

"local": [

"infi-20200730.htm"

]

"labelLink": {

"local": [

"infi-20200730_lab.xml"

"remote": [

"https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"

]

"presentationLink": {

"local": [

"infi-20200730_pre.xml"

]

"referenceLink": {

"remote": [

"https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"

]

"schema": {

"local": [

"infi-20200730.xsd"

"remote": [

"http://www.xbrl.org/2003/xlink-2003-12-31.xsd",

"http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",

"http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",

"http://www.xbrl.org/2003/xl-2003-12-31.xsd",

"https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",

"http://www.xbrl.org/2005/xbrldt-2005.xsd",

"http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",

"http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",

"http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",

"http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",

"http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",

"http://www.xbrl.org/2006/ref-2006-02-27.xsd"

]

}

"elementCount": 24,

"entityCount": 1,

"hidden": {

"http://xbrl.sec.gov/dei/2019-01-31": 2,

"total": 2

"keyCustom": 0,

"keyStandard": 95,

"memberCustom": 0,

"memberStandard": 0,

"nsprefix": "infi",

"nsuri": "http://www.infi.com/20200730",

"report": {

"R1": {

"firstAnchor": {

"ancestors": [

"span",

"div",

"body",

"html"

"baseRef": "infi-20200730.htm",

"contextRef": "i704efe2b73bc42ba8bb2805ac79409c8_D20200730-20200730",

"decimals": null,

"first": true,

"lang": "en-US",

"name": "dei:DocumentType",

"reportCount": 1,

"unique": true,

"unitRef": null,

"xsiNil": "false"

"groupType": "document",

"isDefault": "true",

"longName": "0001001 - Document - Cover",

"role": "http://www.infi.com/role/Cover",

"shortName": "Cover",

"subGroupType": "",

"uniqueAnchor": {

"ancestors": [

"span",

"div",

"body",

"html"

"baseRef": "infi-20200730.htm",

"contextRef": "i704efe2b73bc42ba8bb2805ac79409c8_D20200730-20200730",

"decimals": null,

"first": true,

"lang": "en-US",

"name": "dei:DocumentType",

"reportCount": 1,

"unique": true,

"unitRef": null,

"xsiNil": "false"

}

"segmentCount": 0,

"tag": {

"dei_AmendmentFlag": {

"auth_ref": [],

"lang": {

"en-US": {

"role": {

"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",

"label": "Amendment Flag",

"terseLabel": "Amendment Flag"

}

"localname": "AmendmentFlag",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.infi.com/role/Cover"

"xbrltype": "booleanItemType"

"dei_CityAreaCode": {

"auth_ref": [],

"lang": {

"en-US": {

"role": {

"documentation": "Area code of city",

"label": "City Area Code",

"terseLabel": "City Area Code"

}

"localname": "CityAreaCode",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.infi.com/role/Cover"

"xbrltype": "normalizedStringItemType"

"dei_CoverAbstract": {

"auth_ref": [],

"lang": {

"en-US": {

"role": {

"documentation": "Cover page.",

"label": "Cover [Abstract]"

}

"localname": "CoverAbstract",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"xbrltype": "stringItemType"

"dei_DocumentPeriodEndDate": {

"auth_ref": [],

"lang": {

"en-US": {

"role": {

"documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",

"label": "Document Period End Date",

"terseLabel": "Document Period End Date"

}

"localname": "DocumentPeriodEndDate",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.infi.com/role/Cover"

"xbrltype": "dateItemType"

"dei_DocumentType": {

"auth_ref": [],

"lang": {

"en-US": {

"role": {

"documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",

"label": "Document Type",

"terseLabel": "Document Type"

}

"localname": "DocumentType",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.infi.com/role/Cover"

"xbrltype": "submissionTypeItemType"

"dei_EntityAddressAddressLine1": {

"auth_ref": [],

"lang": {

"en-US": {

"role": {

"documentation": "Address Line 1 such as Attn, Building Name, Street Name",

"label": "Entity Address, Address Line One",

"terseLabel": "Entity Address, Address Line One"

}

"localname": "EntityAddressAddressLine1",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.infi.com/role/Cover"

"xbrltype": "normalizedStringItemType"

"dei_EntityAddressAddressLine2": {

"auth_ref": [],

"lang": {

"en-US": {

"role": {

"documentation": "Address Line 2 such as Street or Suite number",

"label": "Entity Address, Address Line Two",

"terseLabel": "Entity Address, Address Line Two"

}

"localname": "EntityAddressAddressLine2",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.infi.com/role/Cover"

"xbrltype": "normalizedStringItemType"

"dei_EntityAddressCityOrTown": {

"auth_ref": [],

"lang": {

"en-US": {

"role": {

"documentation": "Name of the City or Town",

"label": "Entity Address, City or Town",

"terseLabel": "Entity Address, City or Town"

}

"localname": "EntityAddressCityOrTown",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.infi.com/role/Cover"

"xbrltype": "normalizedStringItemType"

"dei_EntityAddressPostalZipCode": {

"auth_ref": [],

"lang": {

"en-US": {

"role": {

"documentation": "Code for the postal or zip code",

"label": "Entity Address, Postal Zip Code",

"terseLabel": "Entity Address, Postal Zip Code"

}

"localname": "EntityAddressPostalZipCode",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.infi.com/role/Cover"

"xbrltype": "normalizedStringItemType"

"dei_EntityAddressStateOrProvince": {

"auth_ref": [],

"lang": {

"en-US": {

"role": {

"documentation": "Name of the state or province.",

"label": "Entity Address, State or Province",

"terseLabel": "Entity Address, State or Province"

}

"localname": "EntityAddressStateOrProvince",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.infi.com/role/Cover"

"xbrltype": "stateOrProvinceItemType"

"dei_EntityCentralIndexKey": {

"auth_ref": [

"r5"

"lang": {

"en-US": {

"role": {

"documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",

"label": "Entity Central Index Key",

"terseLabel": "Entity Central Index Key"

}

"localname": "EntityCentralIndexKey",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.infi.com/role/Cover"

"xbrltype": "centralIndexKeyItemType"

"dei_EntityEmergingGrowthCompany": {

"auth_ref": [

"r5"

"lang": {

"en-US": {

"role": {

"documentation": "Indicate if registrant meets the emerging growth company criteria.",

"label": "Entity Emerging Growth Company",

"terseLabel": "Entity Emerging Growth Company"

}

"localname": "EntityEmergingGrowthCompany",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.infi.com/role/Cover"

"xbrltype": "booleanItemType"

"dei_EntityFileNumber": {

"auth_ref": [],

"lang": {

"en-US": {

"role": {

"documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",

"label": "Entity File Number",

"terseLabel": "Entity File Number"

}

"localname": "EntityFileNumber",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.infi.com/role/Cover"

"xbrltype": "fileNumberItemType"

"dei_EntityIncorporationStateCountryCode": {

"auth_ref": [],

"lang": {

"en-US": {

"role": {

"documentation": "Two-character EDGAR code representing the state or country of incorporation.",

"label": "Entity Incorporation, State or Country Code",

"terseLabel": "Entity Incorporation, State or Country Code"

}

"localname": "EntityIncorporationStateCountryCode",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.infi.com/role/Cover"

"xbrltype": "edgarStateCountryItemType"

"dei_EntityRegistrantName": {

"auth_ref": [

"r5"

"lang": {

"en-US": {

"role": {

"documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",

"label": "Entity Registrant Name",

"terseLabel": "Entity Registrant Name"

}

"localname": "EntityRegistrantName",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.infi.com/role/Cover"

"xbrltype": "normalizedStringItemType"

"dei_EntityTaxIdentificationNumber": {

"auth_ref": [

"r5"

"lang": {

"en-US": {

"role": {

"documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",

"label": "Entity Tax Identification Number",

"terseLabel": "Entity Tax Identification Number"

}

"localname": "EntityTaxIdentificationNumber",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.infi.com/role/Cover"

"xbrltype": "employerIdItemType"

"dei_LocalPhoneNumber": {

"auth_ref": [],

"lang": {

"en-US": {

"role": {

"documentation": "Local phone number for entity.",

"label": "Local Phone Number",

"terseLabel": "Local Phone Number"

}

"localname": "LocalPhoneNumber",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.infi.com/role/Cover"

"xbrltype": "normalizedStringItemType"

"dei_PreCommencementIssuerTenderOffer": {

"auth_ref": [

"r2"

"lang": {

"en-US": {

"role": {

"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",

"label": "Pre-commencement Issuer Tender Offer",

"terseLabel": "Pre-commencement Issuer Tender Offer"

}

"localname": "PreCommencementIssuerTenderOffer",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.infi.com/role/Cover"

"xbrltype": "booleanItemType"

"dei_PreCommencementTenderOffer": {

"auth_ref": [

"r3"

"lang": {

"en-US": {

"role": {

"label": "Pre-commencement Tender Offer",

"terseLabel": "Pre-commencement Tender Offer"

}

"localname": "PreCommencementTenderOffer",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.infi.com/role/Cover"

"xbrltype": "booleanItemType"

"dei_Security12bTitle": {

"auth_ref": [

"r0"

"lang": {

"en-US": {

"role": {

"documentation": "Title of a 12(b) registered security.",

"label": "Title of 12(b) Security",

"terseLabel": "Title of 12(b) Security"

}

"localname": "Security12bTitle",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.infi.com/role/Cover"

"xbrltype": "securityTitleItemType"

"dei_SecurityExchangeName": {

"auth_ref": [

"r1"

"lang": {

"en-US": {

"role": {

"documentation": "Name of the Exchange on which a security is registered.",

"label": "Security Exchange Name",

"terseLabel": "Security Exchange Name"

}

"localname": "SecurityExchangeName",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.infi.com/role/Cover"

"xbrltype": "edgarExchangeCodeItemType"

"dei_SolicitingMaterial": {

"auth_ref": [

"r4"

"lang": {

"en-US": {

"role": {

"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",

"label": "Soliciting Material",

"terseLabel": "Soliciting Material"

}

"localname": "SolicitingMaterial",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.infi.com/role/Cover"

"xbrltype": "booleanItemType"

"dei_TradingSymbol": {

"auth_ref": [],

"lang": {

"en-US": {

"role": {

"documentation": "Trading symbol of an instrument as listed on an exchange.",

"label": "Trading Symbol",

"terseLabel": "Trading Symbol"

}

"localname": "TradingSymbol",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.infi.com/role/Cover"

"xbrltype": "tradingSymbolItemType"

"dei_WrittenCommunications": {

"auth_ref": [

"r6"

"lang": {

"en-US": {

"role": {

"documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",

"label": "Written Communications",

"terseLabel": "Written Communications"

}

"localname": "WrittenCommunications",

"nsuri": "http://xbrl.sec.gov/dei/2019-01-31",

"presentation": [

"http://www.infi.com/role/Cover"

"xbrltype": "booleanItemType"

}

"unitCount": 0

}

"std_ref": {

"r0": {

"Name": "Exchange Act",

"Number": "240",

"Publisher": "SEC",

"Section": "12",

"Subsection": "b"

"r1": {

"Name": "Exchange Act",

"Number": "240",

"Publisher": "SEC",

"Section": "12",

"Subsection": "d1-1"

"r2": {

"Name": "Exchange Act",

"Number": "240",

"Publisher": "SEC",

"Section": "13e",

"Subsection": "4c"

"r3": {

"Name": "Exchange Act",

"Number": "240",

"Publisher": "SEC",

"Section": "14d",

"Subsection": "2b"

"r4": {

"Name": "Exchange Act",

"Number": "240",

"Publisher": "SEC",

"Section": "14a",

"Subsection": "12"

"r5": {

"Name": "Regulation 12B",

"Number": "240",

"Publisher": "SEC",

"Section": "12",

"Subsection": "b-2"

"r6": {

"Name": "Securities Act",

"Number": "230",

"Publisher": "SEC",

"Section": "425"

}

"version": "2.1"

}

signature=2115bd79e3ad7a14f6ec4efd5feb6a3c,infi-20200730

悦读